Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Gross Profit: 2023-2025

Historic Gross Profit for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to -$3.2 million.

  • Inhibrx Biosciences' Gross Profit was N/A to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.9 million, marking a year-over-year change of. This contributed to the annual value of $200,000 for FY2024, which is 88.89% down from last year.
  • Per Inhibrx Biosciences' latest filing, its Gross Profit stood at -$3.2 million for Q3 2025, which was down 1.27% from -$3.1 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Gross Profit high stood at $1.6 million for Q4 2023, and its period low was -$8.1 million during Q1 2024.
  • Moreover, its 3-year median value for Gross Profit was -$2.7 million (2025), whereas its average is -$2.3 million.
  • Its Gross Profit has fluctuated over the past 5 years, first slumped by 31,635.29% in 2024, then surged by 66.92% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Gross Profit (Quarterly) stood at $1.6 million in 2023, then plummeted by 93.88% to $100,000 in 2024, then skyrocketed by 41.41% to -$3.2 million in 2025.
  • Its Gross Profit was -$3.2 million in Q3 2025, compared to -$3.1 million in Q2 2025 and -$2.7 million in Q1 2025.